After analyzing immune cells in 77 patients with stage II/III colorectal cancer (38 patients receiving NACT), researchers discovered that in the NACT group, the infiltration of CD4+GzmB+ T cells in the central region of the tumors increased, and CD4+GzmB+ T cells were a better prognostic factor for OS and disease-free survival (DFS) (117). The gene discussed is CD4; the disease is colorectal cancer.